Ceftazidime-Avibactam

Restricted
Restricted

C. diff Risk

High

Oral Bioavailability

NA

Approximate Cost

$$$$

Dosing

2.5 g IV q8h

Data is insufficient in the Pediatric population

No adjustment needed

Adjust dose for CrCl

Infectious Diseases consult required for use.

Restricted per UCLA Policy HS 1444. Should be reserved for patients with little or no other treatment alternatives.

Reserved primarily for management of documented infections caused by CRE

General Information

Common Usage

In patients with documented CRE infection

Drug Monitoring

Laboratory

  • CBC, CMP weekly

Clinical

  • Monitor for changes in renal function

Adverse Effects

  • ¬†Diarrhea

  • ¬†Vomiting

  • Hypersensitivity reaction